Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.

NCT06258746 | Unknown Phase 1

• 1 other identifier: HSK31679-102
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK31679 in healthy male subjects.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Mass balance

  Percentage of cumulative drug excretion of \[14C\]HSK31679 on biological pecimens(urine and faeces) accounting for total radiation drug dose

  From the start of administration to 240 hours after administration

Secondary Outcomes (3)

• AUC(0-t)

  From the start of administration to 240 hours after administration

• AUC(0-∞)

  From the start of administration to 240 hours after administration

• Cmax

  From the start of administration to 240 hours after administration

Study Arms (1)

160 mg/100 μCi [14C]HSK31679

EXPERIMENTAL

\[14C\]HSK31679

Drug: [14C]HSK31679

Interventions

[14C]HSK31679 DRUG

A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.

160 mg/100 μCi [14C]HSK31679

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: Male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male subjects, Age: 18\~45 years old (inclusive);
• A total body weight ≥50 kg and BMI of 19 to 26 kg/m\^2(inclusive);
• Subjects who are willing to sign an informed consent form, able to communicate with the investigator and to complete all trial procedures as per the protocol.

You may not qualify if:

• Clinically significant abnormal results for comprehensive physical examination, vital signs, routine laboratory tests \[blood routine, blood biochemistry, coagulation routine, urine routine, Fecal analysis, thyroid function and antibodies, visual acuity and ophthalmic examination (slit lamp, introcular pressure, and fundoscopy), 12-lead electrocardiogram (ECG), chest X-ray (anteriorposterior), and abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, and kidney);
• Positive for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, or Treponema pallidum antibodies;
• Use of any Western medicine or Chinese patent medicine (including prescription drug, over-the-counter drug, health care product, or live attenuated influenza vaccine) within 14 days prior to screening;
• Participation in any clinical trial and interference with other investigational drug or medical device within 3 month prior to screening;
• Any clinical serious illness that has previously or currently affected the cardiovascular system, digestive system, respiratory system, endocrine system, nervous system, hematology, immunology, skin, tumors, psychiatry, and metabolic abnormalities, or any other disease or physiological condition that can interfere with trial results;
• Have undergone major surgery within 6 months prior to screening or with incomplete healing of the surgical incision; major surgery includes, but is not limited to, any surgery with significant risk of bleeding, prolonged general anesthesia, or incisional biopsy or obvious traumatic injury (excluding cured appendicitis surgery or rectal prolapse surgery);
• Severe allergic constitution, including known allergy to THR- β receptor agonists or any excipient of this investigational product, two or more drugs and food components, or with special dietary requirements and thus unable to follow a standardized diet;
• Concomitant hemorrhoids or perianal diseases with regular/ongoing rectal bleeding;
• Subjects who had Irregular bowel movements or diarrhea, irritable bowel syndrome, inflammatory bowel disease;
• Excessive drinking or frequent drinking within the first 6 months of the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit=360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine); Positive alcohol breath test during the screening period;
• Subjects who smoked more than 5 cigarettes a day or habitually used nicotine-containing products in the 3 months before the screening period and could not quit during the test period;
• Drug abuse or dependence, urine screening positive for drug abuse;
• Habitually drinking grapefruit juice or excessive (more than 8 cups a day, 1 cup =250mL) tea, grapefruit, coffee, drinks containing caffeine or grapefruit, and could not quit during the test period;
• Subjects who need to work in a condition with long-term radioactive exposure; or who have experienced significant radioactive exposure (≥2 chest/abdominal CT scans, or ≥3 other types of X-rays) within 1 year or participated in the radiopharma labeling test prior to the test;
• Subjects who have a birth plan during the study period and within 1 year after completion of the study, or who don't agree that the subject and his or her spouse should take strict contraceptive measures (condoms, contraceptive sponges, contraceptive gels, contraceptive membranes, intrauterine devices, oral or injectable contraceptives, subcutaneous implants, etc.) during the study period and within 1 year after completion of the study;

Sponsors & Collaborators

• Xizang Haisco Pharmaceutical Co., Ltd: lead

Study Sites (1)

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

Jinan, Shandong, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2024
• First Posted: February 14, 2024
• Study Start: December 5, 2023
• Primary Completion: December 21, 2023
• Study Completion: December 30, 2024
• Last Updated: August 20, 2024

Record last verified: 2024-01

Locations

CN (1)